{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:19Z","timestamp":1793650459349,"version":"4.5.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R15NS118352"],"award-info":[{"award-number":["R15NS118352"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.neuropharm.2023.109774","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T19:49:10Z","timestamp":1699040950000},"page":"109774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-2109","authenticated-orcid":false,"given":"Tanishka S.","family":"Saraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9228-6311","authenticated-orcid":false,"given":"Richa","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-933X","authenticated-orcid":false,"given":"Clinton E.","family":"Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109774_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2010.05.002","article-title":"Early developmental alterations in GABAergic protein expression in fragile X knockout mice","volume":"59","author":"Adusei","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41467-017-01191-2","article-title":"Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice","volume":"8","author":"Aloisi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109774_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2011.01.015","article-title":"Serotonergic regulation of neuronal excitability in the prefrontal cortex","volume":"61","author":"Andrade","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/acsptsci.9b00101","volume":"3","author":"Armstrong","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0893-133X(96)80057-1","article-title":"Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells","volume":"14","author":"Azmitia","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0006-8993(02)03727-7","article-title":"The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain","volume":"959","author":"Aznar","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109774_bib9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-8749.2002.tb00277.x","article-title":"Epilepsy in fragile X syndrome","volume":"44","author":"Berry-Kravis","year":"2002","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-8749.2002.tb00277.x","article-title":"Epilepsy in fragile X syndrome","volume":"44","author":"Berry-Kravis","year":"2007","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1097-4547(19980101)51:1<41::AID-JNR4>3.0.CO;2-L","article-title":"Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells","volume":"51","author":"Berry-Kravis","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.736255","article-title":"Seizures in fragile X syndrome: associations and longitudinal analysis of a large clinic-based cohort","volume":"9","author":"Berry-Kravis","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.neuropharm.2023.109774_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.410310105","article-title":"Cyclic-amp metabolism in fragile-X syndrome","volume":"31","author":"Berry-Kravis","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1352\/1944-7558-115.6.461","article-title":"Seizures in fragile X syndrome: characteristics and comorbid diagnoses","volume":"115","author":"Berry-Kravis","year":"2010","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.neuropharm.2023.109774_bib15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109774_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1203\/00006450-199511000-00002","article-title":"Reduced cyclic-amp production in fragile-X syndrome - cytogenetic and molecular correlations","volume":"38","author":"Berry-Kravis","year":"1995","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51890","article-title":"Auditory cortex shapes sound responses in the inferior colliculus","volume":"9","author":"Blackwell","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109774_bib19","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/ajmg.a.38373","article-title":"Epilepsy in fragile-X-syndrome mimicking panayiotopoulos syndrome: description of three patients","volume":"173","author":"Bonanni","year":"2017","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neuropharm.2023.109774_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41593-020-00792-3","article-title":"Increasing the statistical power of animal experiments with historical control data","volume":"24","author":"Bonapersona","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuroscience.2018.05.012","article-title":"Abnormal sleep architecture and hippocampal circuit dysfunction in a mouse model of fragile X syndrome","volume":"384","author":"Boone","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109774_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neubiorev.2016.06.033","article-title":"Hippocampal dysfunction and cognitive impairment in Fragile-X Syndrome","volume":"68","author":"Bostrom","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109774_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0197-0186(96)00124-6","article-title":"[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia","volume":"30","author":"Burnet","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2023.109774_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschemneuro.5b00099","article-title":"An orally active phenylaminotetralin-chemotype serotonin 5-HT7 and 5-ht1a receptor partial agonist that corrects motor stereotypy in mouse models","volume":"6","author":"Canal","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-010-1784-0","article-title":"The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen","volume":"209","author":"Canal","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109774_bib26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1021\/acschemneuro.7b00087","article-title":"Classics in chemical neuroscience: aripiprazole","volume":"8","author":"Casey","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"18","key":"10.1016\/j.neuropharm.2023.109774_bib95","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/WNR.0000000000001366","article-title":"Citalopram reduces glutamatergic synaptic transmission in the auditory cortex via activation of 5-HT1A receptors","volume":"30","author":"Cervantes-Ramirez","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2023.109774_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2016.00136","article-title":"Multiple drug treatments that increase cAMP signaling restore long-term memory and aberrant signaling in fragile X syndrome models","volume":"10","author":"Choi","year":"2016","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuron.2015.06.017","article-title":"Altered neuronal and circuit excitability in fragile X syndrome","volume":"87","author":"Contractor","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109774_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0006-8993(03)03352-3","article-title":"Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex","volume":"989","author":"Czyrak","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainres.2006.08.115","article-title":"Decreased expression of the GABAA receptor in fragile X syndrome","volume":"1121","author":"D'Hulst","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/nn.3379","article-title":"The translation of translational control by FMRP: therapeutic targets for FXS","volume":"16","author":"Darnell","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib33","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.celrep.2016.08.046","article-title":"Increased persistent sodium current causes neuronal hyperexcitability in the entorhinal cortex of Fmr1 knockout mice","volume":"16","author":"Deng","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109774_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41583-021-00445-9","article-title":"Channelopathies in fragile X syndrome","volume":"22","author":"Deng","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib35","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s10803-019-04173-z","article-title":"Pharmacologic interventions for irritability, aggression, agitation and self-injurious behavior in fragile X syndrome: an initial cross-sectional analysis","volume":"49","author":"Eckert","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2023.109774_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2004.11.087","article-title":"Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse","volume":"377","author":"El Idrissi","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109774_bib37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","article-title":"Aripiprazole in autism spectrum disorders and fragile X syndrome","volume":"7","author":"Erickson","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2023.109774_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-011-2194-7","article-title":"A prospective open-label study of aripiprazole in fragile X syndrome","volume":"216","author":"Erickson","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109774_bib39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0166-4328(96)00118-0","article-title":"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist","volume":"73","author":"Fletcher","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib40","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1152\/jn.90752.2008","article-title":"Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome","volume":"100","author":"Gibson","year":"2008","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib41","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1523\/JNEUROSCI.0886-19.2019","article-title":"Audiogenic seizures in the Fmr1 knock-out mouse are induced by Fmr1 deletion in subcortical, VGlut2-expressing excitatory neurons and require deletion in the inferior colliculus","volume":"39","author":"Gonzalez","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF00216019","article-title":"The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)","volume":"91","author":"Goodwin","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109774_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15028-x","article-title":"Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)","volume":"7","author":"Gurney","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109774_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: a systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vascn.2014.07.003","article-title":"Role of 5-HT1A- and 5-HT2A receptors for the murine model of the serotonin syndrome","volume":"70","author":"Haberzettl","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2023.109774_bib46","article-title":"Fragile X syndrome","volume":"3","author":"Hagerman","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2023.109774_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuron.2010.01.024","article-title":"Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice","volume":"65","author":"Harlow","year":"2010","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109774_bib94","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1152\/jn.00046.2006","article-title":"Different serotonin receptor agonists have distinct effects on sound-evoked responses in inferior colliculus","volume":"96","author":"Hurley","year":"2006","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.neuropharm.2023.109774_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2007.08.053","article-title":"Activation of the serotonin 1A receptor alters the temporal characteristics of auditory responses in the inferior colliculus","volume":"1181","author":"Hurley","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.neuropharm.2023.109774_bib48","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s11064-022-03577-1","article-title":"The role of 5-ht1a receptors and neuronal nitric oxide synthase in a seizur induced kindling model in rats","volume":"47","author":"Kalati","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib49","doi-asserted-by":"crossref","first-page":"13111","DOI":"10.1523\/JNEUROSCI.1347-12.2012","article-title":"Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila","volume":"32","author":"Kanellopoulos","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib50","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41593-021-00913-6","article-title":"A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies","volume":"24","author":"Kang","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib51","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1542\/peds.2016-1159F","article-title":"Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment","volume":"139","author":"Kaufmann","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2023.109774_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000931","article-title":"The cyclic AMP cascade is altered in the fragile X nervous system","volume":"2","author":"Kelley","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109774_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/(SICI)1097-4547(19961215)46:6<697::AID-JNR7>3.0.CO;2-A","article-title":"Ultrastructural localization of 5-hydroxytryptamine(1A) receptors in the rat brain","volume":"46","author":"Kia","year":"1996","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib54","article-title":"Differential regulation of BK channels by fragile X mental retardation protein","volume":"152","author":"Kshatri","year":"2020","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib55","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.neuropharm.2023.109774_bib56","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","article-title":"5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons","volume":"22","author":"Llado-Pelfort","year":"2012","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109774_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nbd.2018.03.012","article-title":"Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome","volume":"115","author":"Lovelace","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109774_bib58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cercor\/bhz141","article-title":"Deletion of Fmr1 from forebrain excitatory neurons triggers abnormal cellular, EEG, and behavioral phenotypes in the auditory cortex of a mouse model of fragile X syndrome","volume":"30","author":"Lovelace","year":"2020","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109774_bib59","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1073\/pnas.0404995101","article-title":"The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development","volume":"101","author":"Lu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109774_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185067","article-title":"Excitability is increased in hippocampal CA1 pyramidal cells of Fmr1 knockout mice","volume":"12","author":"Luque","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109774_bib61","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1093\/cercor\/bhy192","article-title":"Involvement of phosphodiesterase 2A activity in the pathophysiology of fragile X syndrome","volume":"29","author":"Maurin","year":"2019","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109774_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neubiorev.2014.12.001","article-title":"Sensitive and critical periods during neurotypical and aberrant neurodevelopment: a framework for neurodevelopmental disorders","volume":"50","author":"Meredith","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109774_bib63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.tins.2012.03.005","article-title":"Sensitive time-windows for susceptibility in neurodevelopmental disorders","volume":"35","author":"Meredith","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1157.2000.tb01499.x","article-title":"Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome","volume":"41","author":"Musumeci","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2023.109774_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107937","article-title":"Translating biased agonists from molecules to medications: serotonin 5-HT(1A) receptor functional selectivity for CNS disorders","volume":"229","author":"Newman-Tancredi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109774_bib66","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1021\/acschemneuro.2c00404","article-title":"Hemispheric utilization of alpha oscillatory dynamics as a unique biomarker of neural compensation in females with fragile X syndrome","volume":"13","author":"Norris","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0169-328X(96)00026-5","article-title":"Comparative anatomical distribution of serotonin 1A, 1D alpha and 2A receptor mRNAs in human brain postmortem","volume":"39","author":"Pasqualetti","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.720752","article-title":"Neural correlates of auditory hypersensitivity in fragile X syndrome","volume":"12","author":"Razak","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109774_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A","article-title":"Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain","volume":"417","author":"Riad","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib72","series-title":"National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) Assay Protocol Book","author":"Roth","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109774_bib73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2016.12.010","article-title":"Impaired GABAergic inhibition in the hippocampus of Fmr1 knockout mice","volume":"116","author":"Sabanov","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cne.21810","article-title":"Distribution and neurochemical characterization of neurons expressing GIRK channels in the rat brain","volume":"510","author":"Saenz del Burgo","year":"2008","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib75","first-page":"60","article-title":"Fragile X syndrome: clinical presentation, pathology and treatment","volume":"156","author":"Salcedo-Arellano","year":"2020","journal-title":"Gac. Med. Mex."},{"key":"10.1016\/j.neuropharm.2023.109774_bib76","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109774_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106677","article-title":"Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice","volume":"175","author":"Saraf","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2023.109774_bib78","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1021\/acschemneuro.2c00574","article-title":"FPT, a 2-aminotetralin, is a potent serotonin 5-HT(1A), 5-HT(1B), and 5-HT(1D) receptor agonist that modulates cortical electroencephalogram activity in adult Fmr1 knockout mice","volume":"13","author":"Saraf","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib79","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R4662","article-title":"Targeting 5-ht1a receptors to correct neuronal hyperexcitability in Fmr1 knockout mice","volume":"36","author":"Saraf","year":"2022","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2023.109774_bib80","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302534120","article-title":"Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP","volume":"120","author":"Shah","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109774_bib81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnbeh.2013.00140","article-title":"Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia","volume":"7","author":"Sumiyoshi","year":"2013","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109774_bib83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroscience.2022.11.014","article-title":"Acute and repeated administration of NLX-101, a selective serotonin-1A receptor biased agonist, reduces audiogenic seizures in developing Fmr1 knockout mice","volume":"509","author":"Tao","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109774_bib84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.bjp.0701946","article-title":"Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719","volume":"124","author":"Thomas","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11689-010-9047-2","article-title":"Aging in fragile X syndrome","volume":"2","author":"Utari","year":"2010","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neuropharm.2023.109774_bib86","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1113\/JP271190","article-title":"GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome","volume":"593","author":"Wahlstrom-Helgren","year":"2015","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/hmg\/ddh009","article-title":"Developmentally-programmed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors","volume":"13","author":"Wang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2023.109774_bib88","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","article-title":"Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP","volume":"49","author":"Yan","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109774_bib89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.expneurol.2016.03.025","article-title":"Altered intrinsic properties and bursting activities of neurons in layer IV of somatosensory cortex from Fmr-1 knockout mice","volume":"280","author":"Zhang","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.08.008","article-title":"Decreased surface expression of the delta subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome","volume":"297","author":"Zhang","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109774_bib91","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/nn.3864","article-title":"Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1(-\/y) mice","volume":"17","author":"Zhang","year":"2014","journal-title":"Nat. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823003647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823003647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:49:18Z","timestamp":1719985758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823003647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":90,"alternative-id":["S0028390823003647"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109774","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109774"}}